205 related articles for article (PubMed ID: 33603372)
41. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
[TBL] [Abstract][Full Text] [Related]
42. Anti-cancerous efficacy and pharmacokinetics of 6-mercaptopurine loaded chitosan nanoparticles.
Kumar GP; Sanganal JS; Phani AR; Manohara C; Tripathi SM; Raghavendra HL; Janardhana PB; Amaresha S; Swamy KB; Prasad RG
Pharmacol Res; 2015 Oct; 100():47-57. PubMed ID: 26232590
[TBL] [Abstract][Full Text] [Related]
43. Association of
Kodidela S; Dorababu P; Thakkar DN; Dubashi B; Sundaram R; Muralidharan N; Nidanapu RP; Aribandi A; Pradhan SC; Uppugunduri CRS
Genes (Basel); 2020 May; 11(6):. PubMed ID: 32481505
[TBL] [Abstract][Full Text] [Related]
44. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
[TBL] [Abstract][Full Text] [Related]
45. Mechanistic mathematical modelling of mercaptopurine effects on cell cycle of human acute lymphoblastic leukaemia cells.
Panetta JC; Evans WE; Cheok MH
Br J Cancer; 2006 Jan; 94(1):93-100. PubMed ID: 16333308
[TBL] [Abstract][Full Text] [Related]
46. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
[TBL] [Abstract][Full Text] [Related]
47. Application and Analysis of 6-Mercaptopurine Nanomedicine in the Treatment of Leukemia.
Lu X; Xie Y; Wang F
J Nanosci Nanotechnol; 2021 Feb; 21(2):1001-1007. PubMed ID: 33183436
[TBL] [Abstract][Full Text] [Related]
48. Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children.
Mawatari H; Unei K; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2001 Dec; 43(6):673-7. PubMed ID: 11737747
[TBL] [Abstract][Full Text] [Related]
49. PLGA-PEG-PLGA triblock copolymeric micelles as oral drug delivery system: In vitro drug release and in vivo pharmacokinetics assessment.
Chen X; Chen J; Li B; Yang X; Zeng R; Liu Y; Li T; Ho RJY; Shao J
J Colloid Interface Sci; 2017 Mar; 490():542-552. PubMed ID: 27923139
[TBL] [Abstract][Full Text] [Related]
50. BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy.
Slone WL; Moses BS; Hare I; Evans R; Piktel D; Gibson LF
Oncotarget; 2016 Apr; 7(17):23439-53. PubMed ID: 27015556
[TBL] [Abstract][Full Text] [Related]
51. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance.
Fakler M; Loeder S; Vogler M; Schneider K; Jeremias I; Debatin KM; Fulda S
Blood; 2009 Feb; 113(8):1710-22. PubMed ID: 19036706
[TBL] [Abstract][Full Text] [Related]
52. Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.
Aldana-Masangkay GI; Rodriguez-Gonzalez A; Lin T; Ikeda AK; Hsieh YT; Kim YM; Lomenick B; Okemoto K; Landaw EM; Wang D; Mazitschek R; Bradner JE; Sakamoto KM
Leuk Lymphoma; 2011 Aug; 52(8):1544-55. PubMed ID: 21699378
[TBL] [Abstract][Full Text] [Related]
53. Polymeric Nanomedicine for Combined Gene/Chemotherapy Elicits Enhanced Tumor Suppression.
Xu B; Xia S; Wang F; Jin Q; Yu T; He L; Chen Y; Liu Y; Li S; Tan X; Ren K; Yao S; Zeng J; Song X
Mol Pharm; 2016 Feb; 13(2):663-76. PubMed ID: 26695934
[TBL] [Abstract][Full Text] [Related]
54. Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluation.
Hu S; Zhang Y
Int J Nanomedicine; 2010 Nov; 5():1039-48. PubMed ID: 21170352
[TBL] [Abstract][Full Text] [Related]
55. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
56. Impact of
Ruel NM; Nguyen KH; Kim CS; Andrade LPS; Hammond JR
J Pharmacol Exp Ther; 2022 Sep; 382(3):335-345. PubMed ID: 35798387
[TBL] [Abstract][Full Text] [Related]
57. Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.
Farfan MJ; Salas C; Canales C; Silva F; Villarroel M; Kopp K; Torres JP; Santolaya ME; Morales J
BMC Cancer; 2014 Apr; 14():299. PubMed ID: 24774509
[TBL] [Abstract][Full Text] [Related]
58. APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.
Kim H; Seo H; Park Y; Min BJ; Seo ME; Park KD; Shin HY; Kim JH; Kang HJ
Cancer Res Treat; 2018 Jul; 50(3):823-834. PubMed ID: 28882023
[TBL] [Abstract][Full Text] [Related]
59. Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Schmiegelow K; Nielsen SN; Frandsen TL; Nersting J
J Pediatr Hematol Oncol; 2014 Oct; 36(7):503-17. PubMed ID: 24936744
[TBL] [Abstract][Full Text] [Related]
60. Apatinib exhibits anti-leukemia activity in preclinical models of acute lymphoblastic leukemia.
Deng M; Zha J; Jiang Z; Jia X; Shi Y; Li P; Chen XL; Fang Z; Du Z; Xu B
J Transl Med; 2018 Feb; 16(1):47. PubMed ID: 29490645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
